ArticleBreast cancer research : BCR2026
Diagnostic plasma protein signatures in sporadic and BRCA1/2 breast cancer patients via targeted proteomics.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEarly breast cancer diagnosis is critical, particularly for individuals at hereditary risk. The aim of this study was to identify blood-derived protein biomarkers for breast cancer diagnosis to improve current screening strategies.
methodsAbsolute quantification of 98 plasma proteins was performed via a UPLC-MRM-MS assay on plasma samples from 135 breast cancer patients and paired controls, one-third of which were of hereditary BRCA1/2 origin, and from women diagnosed within 5 years from blood collection. Plasma protein concentration profiles were compared between patients and paired controls across breast cancer subgroups.
resultsProteomic analysis revealed four plasma proteins with elevated abundance and four other proteins with reduced abundance across different breast cancer subgroups. Haptoglobin (HP) was elevated in sporadic cases (n = 88) and cases with grade 3 tumors (n = 44), adipocyte plasma membrane-associated protein was elevated in cases with large tumors (n = 60) and grade 3 tumors (n = 44), lipopolysaccharide-binding protein (LBP) was elevated in node-positive (n = 58) and HER2 (n = 9) cases, and secreted protein acidic and cysteine rich was elevated in luminal B (n = 45) cases. Transthyretin was reduced in luminal B patients, and apolipoprotein A4 was reduced in HER2 patients. Immunoglobulin heavy constant mu (IGHM) and CD5 antigen-like (CD5L) were lower in BRCA1/2 (n = 47) and triple-negative (n = 17) patients than in paired controls. IGHM and CD5L were also lower in BRCA1/2 patients than in paired sporadic patients. Additionally, IGHM in plasma was lower among BRCA2 mutation carriers (n = 7) diagnosed with breast cancer within 5 years of blood collection than among paired controls and CD5L was also lower than among paired controls and sporadic patients diagnosed within 5 years of blood collection. The plasma proteins associated with breast cancer specific survival were LBP, HP, and IGHM.
conclusionsThese findings indicate that plasma protein concentrations may have diagnostic and prognostic value for breast cancer screening and could provide valuable insights for biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.